Related Experiment Videos
Iron chelation
1Department of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.
Insights
Iron chelation therapy significantly improves survival in thalassemia patients, reducing cardiac mortality. New oral iron chelators show promise, potentially replacing desferrioxamine (DF) in future treatments.
Area of Science:
- Hematology
- Pharmacology
- Cardiology
Background:
- Thalassemia treatment relies on iron chelation to manage iron overload.
- Desferrioxamine (DF) has improved survival rates but requires intensive administration.
- Cardiac complications remain a significant concern in thalassemia patients.
Purpose of the Study:
- To review the impact of iron chelation therapy on thalassemia outcomes.
- To discuss current and emerging iron chelation strategies.
- To explore novel applications of iron chelators beyond iron overload.
Main Methods:
- Review of long-term desferrioxamine (DF) therapy protocols.
- Analysis of DF efficacy in established cardiomyopathy.
- Examination of experimental uses of DF in inflammatory conditions and protozoal infections.
- Overview of research into orally effective iron chelators.
Main Results:
- Adequate iron chelation has dramatically improved survival, reducing cardiac mortality and increasing life expectancy.
- Early initiation of DF (2-4 years) and optimized administration (subcutaneous, IV) are crucial.
- Continuous IV DF can improve myocardial function in patients with cardiomyopathy.
- DF shows potential in non-iron overload conditions by preventing free-radical formation and inhibiting cell proliferation.
- Several orally effective iron chelators superior to DF have been identified and are undergoing toxicity testing.
Conclusions:
- Iron chelation therapy is vital for improving survival and quality of life in thalassemia.
- Optimized DF administration and novel therapeutic applications are expanding its utility.
- Development of orally effective iron chelators represents a significant advancement, with promising candidates nearing clinical use.
Abstract:
Adequate iron chelation in thalassaemia has resulted in a striking improvement in survival, with a reduction of cardiac mortality at age 15 years from 14-3%, and a predicted survival at age 36 years of 85%. Long term desferrioxamine (DF) therapy in thalassaemic children should be started between 2-4 years of age. In addition to daily 8-12 h subcutaneous infusions, intermittent high dose (9-16 g) i.v. supplementation over 24-48 h may be given on the occasion of blood transfusions. In established myocardiopathy continuous i.v. DF infusion at 100-125 mg/kg/d may result in improved myocardial function. In addition, there is considerable current interest in the use of DF in conditions unrelated to iron overload by preventing the formation of free-radicals in inflammatory reactions, or by S-phase inhibition of cell proliferation. Although at present highly experimental, this novel approach may have important implications for the management of patients with inflammatory conditions and perhaps in the control of protozoal infections. Over the last decade several hundred candidate compounds have been studied in cell cultures and in animal models and a number of orally effective iron chelators have been identified, all of which are superior to DF in their in vivo iron chelating effect. Although we do not yet have a new drug which is immediately available for replacing DF in clinical practice, significant progress has already been made, and some of the most promising candidate drugs are currently undergoing extensive toxicity tests in anticipation of their development for large-scale clinical use.